Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
NCT ID: NCT02037737
Last Updated: 2018-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
153 participants
OBSERVATIONAL
2016-09-30
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
NCT01142726
Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
NCT00095147
A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate
NCT00345748
A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT00409838
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
NCT02504268
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Other: ReACTION is a study using secondary data originally collected in ACTION study. In ACTION, data were collected prospectively from October 2010 up to 2015 at each clinical visit. In France, data collection started in June 2011
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RA patients on Abatacept IV
Rheumatoid Arthritis (RA) patients with inadequate response to one or more conventional DMARDs including Methotrexate and treated with Abatacept IV according to routine clinical practice in France
Abatacept
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Abatacept
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female subjects of more than 18 years old
* Patients with a diagnosis of established moderate to severe active RA
* Patients who at their physician's discretion are treated with Abatacept (initiated or already on treatment within 3 months) according to routine clinical practice
* Patients for whom baseline characteristics are available
* Patients consent for usage of their data in ACTION study
* Patients who were not included in any interventional clinical trial in RA
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM101-409
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.